Format

Send to

Choose Destination
J Obstet Gynaecol Can. 2010 Dec;32(12):1167-1171. doi: 10.1016/S1701-2163(16)34741-7.

Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura.

Author information

1
Faculty of Medicine, University of British Columbia Vancouver BC.

Abstract

BACKGROUND:

Rituximab is a novel therapy for immune thrombocytopenic purpura (ITP); however, information about its safety in pregnancy is limited. This case illustrates the successful use of rituximab to treat pregnancy-associated ITP.

CASE:

A 34-year-old woman presented with severe ITP at 23 weeks' gestation. Standard treatment with corticosteroids, intravenous immune globulin, and splenectomy failed to raise the platelet count. Due to ongoing bleeding, rituximab was given in the 26th week of pregnancy. The platelet count rose to over 100 × 10(9)/L after four weeks. The neonatal B-lymphocyte count normalized at four months after delivery. There were no neonatal complications of rituximab therapy.

CONCLUSION:

Rituximab may be safe for use in treating pregnancy-associated ITP. This case highlights the need to investigate further the safety and efficacy of rituximab in pregnancy.

PMID:
21176329
DOI:
10.1016/S1701-2163(16)34741-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center